Evaluation of Anti-platelet Aggregation Activity and Compatibility Patterns of 58 Kinds of Compound Traditional Chinese Medicines for Promoting Blood Circulation and Removing Blood Stasis
|更新时间:2024-01-04
|
Evaluation of Anti-platelet Aggregation Activity and Compatibility Patterns of 58 Kinds of Compound Traditional Chinese Medicines for Promoting Blood Circulation and Removing Blood Stasis
Chinese Journal of Experimental Traditional Medical FormulaeVol. 22, Issue 24, Pages: 187-193(2016)
MENG Yan-zhi, WANG Zhi-long, SU Jun-cheng, et al. Evaluation of Anti-platelet Aggregation Activity and Compatibility Patterns of 58 Kinds of Compound Traditional Chinese Medicines for Promoting Blood Circulation and Removing Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(24): 187-193.
DOI:
MENG Yan-zhi, WANG Zhi-long, SU Jun-cheng, et al. Evaluation of Anti-platelet Aggregation Activity and Compatibility Patterns of 58 Kinds of Compound Traditional Chinese Medicines for Promoting Blood Circulation and Removing Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(24): 187-193. DOI: 10.13422/j.cnki.syfjx.2016240187.
Evaluation of Anti-platelet Aggregation Activity and Compatibility Patterns of 58 Kinds of Compound Traditional Chinese Medicines for Promoting Blood Circulation and Removing Blood Stasis
Objective: To evaluate the anti-platelet aggregation activities of the Chinese patent medicines (CPM) for promoting blood circulation and removing blood stasis
explore the medication rules
and provide certain experimental basis for the development of anti platelet drugs. Method: High-throughput microwell turbidimetric method was used to detect drug response to platelet aggregation induced by adenosine diphosphate (ADP) and thrombin. Result: The 41 kinds of tested Chinese patent medicines (CPM) showed antagonistic effect in different degrees (inhibitory rate of 30%~98%) on platelet aggregation induced by ADP or thrombin. 18 kinds of CPM among them showed selectivity for the inducers. Formulation analysis revealed that highest anti-platelet aggregation activities were demonstrated by the CPM containing ingredients of Salviae Miltiorrhizae Radix et Rhizoma
Chuanxiong Rhizoma
Carthami Flos
Notoginseng Radix et Rhizoma
and Borneolum Syntheticum. Furthermore
the CPMs with promoting blood circulation character were more frequently combined with those of multi-tonic medicine
resuscitation medicine and hemostatic medicine to achieve more potent inhibitory effects on platelet aggregation. Conclusion: The compound CPMs for promoting blood circulation and removing blood stasis can achieve anti-platelet aggregation activity by anti-ADP and antithrombin means. The medicines with ‘Qi-regulating’
‘Qi-tonifying’ and ‘resuscitation’ efficacy may strengthen the activity of anti-platelet aggregation.
Exploring Modern Mechanism of Treating Diabetic Retinopathy and Coronary Heart Disease from Perspective of Blood Stasis Under Viewpoint of Treating Different Diseases with the Same Method
Research Progress of Different Components of Traditional Chinese Medicine in Treatment of Blood Stasis Syndrome
The Advance in Complex Prescription Compatibility Law of Traditional Chinese Medicine
Prescriptions Compatibility Law Research for Stroke Treatment in Hui Medicine
Inhibition of Platelet Aggregation Investigation and Optimization of Extracting Technology of 6,7-Dehydroroyleanone in Roots of Schang
Related Author
LIU Yue
LIU Yanfei
XU Shihan
WANG Wenting
WANG Ziyu
Yue-nan FENG
Yu-kun ZHANG
Si-miao SUN
Related Institution
National Clincial Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Xiyuan Hospital,China Academy of Chinese Medical Sciences